Leading multinational pharmaceutical companies often only have a small presence in the Turkish market, often through a single manufacturing plant and commercial headquarters. However, with Turkey aligning itself with European regulatory standards and with government measures to stimulate R&D, more companies are expected to expand their footprint in Turkey in the future.
Features and benefits
- Understand drivers and resistors for accessing the Turkish pharmaceutical market
- Analyze ongoing trends in the R&D and manufacturing sector in Turkey
- Examine the leading pharmaceutical companies in Turkey, their infrastructure and current strategy in this market
- Overview of outsourcing and distribution trends in the Turkish pharmaceutical market
The pharmaceutical market in Turkey was valued at $9.2bn in 2010, having grown by 6.9% between 2009 and 2010, and posting a compound annual growth rate of 9.5% over 2003–10.
Several companies are capitalizing on Turkey’s benefits for conducting clinical trials, aided by new government measures aimed at encouraging investments in R&D, improved clinical trial regulations and Turkey’s large treatment-naïve population and low costs.
However, factors anticipated to negatively impact future growth of the branded pharma market include the recent government price cuts, negatively impacting market attractiveness. In addition, the lack of incentives for small and medium sized pharma companies has resulted in limited R&D activity in Turkey.
Your key questions answered
- What are the government subsidies to facilitate investments in the Turkish market?
- Which are the top 10 pharmaceutical companies, and how have these expanded their business operations?